PubMed · 15912968
FK-778 Astellas.
Abstract
Astellas, under license from sanofi-aventis, is developing the immunosuppressant compound FK-778 as a potential treatment for organ transplantation. By February 2005, phase II trials were ongoing both in the US and in Europe.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Mariana J Kaplan. 2005. FK-778 Astellas.. https://pubmed.ncbi.nlm.nih.gov/15912968/
Cite the original work for its findings. Save a collection to share your selection of sources.